SCHEMBL10269338

SCHEMBL10269338

COc1cc(NC(=O)c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c(OC)cc1NC(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
HDAC2 Q92769 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
MAPT P10636 2/20 0.44
MAPK1 P28482 1/20 0.44
AHR P35869 1/20 0.44
KDR P35968 2/20 0.44
PDGFRB P09619 1/20 0.44
MAPKAPK2 P49137 5/20 0.44
ALDH1A1 P00352 2/20 0.44
TNFRSF1A P19438 1/20 0.42
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
THRB P10828 1/20 0.41
RECQL P46063 1/20 0.41
BLM P54132 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10269330 0.91 NPC1 (0.47) MEN1KMT2AMAPTAHRKDR
SCHEMBL10269032 0.90 MAPT (0.47) MEN1KMT2AHDAC2SMN1; SMN2MAPT
SCHEMBL10269655 0.90 MEN1 (0.51) MEN1KMT2ASMN1; SMN2MAPTMAPK1
SCHEMBL10269192 0.89 KDR (0.42) MEN1KMT2ASMN1; SMN2MAPTKDR
SCHEMBL10268552 0.88 CYP1A2 (0.45) SMN1; SMN2MAPTKDRMAPKAPK2ALDH1A1
SCHEMBL10269034 0.87 ALDH1A1 (0.55) MEN1KMT2ASMN1; SMN2MAPTKDR
SCHEMBL10269606 0.85 TP53 (0.45) MEN1KMT2AKDRPDGFRBMAPKAPK2
SCHEMBL10269327 0.84 MAPKAPK2 (0.47) MEN1KMT2AHDAC2SMN1; SMN2MAPT
SCHEMBL10269605 0.84 MAPKAPK2 (0.49) MEN1KMT2AHDAC2KDRPDGFRB
SCHEMBL10269197 0.84 MAPKAPK2 (0.52) HDAC2KDRPDGFRBMAPKAPK2CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-8008481-B2 Indazole compounds ABBVIE INC. 2011-08-30 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 MEN1 878/4885KMT2A 3965/4885HDAC2 148/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 MEN1 878/4885KMT2A 3965/4885HDAC2 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.